Hannah Elena Suhrs1, Kristoffer Flintholm Raft2, Kira Bové2, Steen Madsbad3, Jens Juul Holst4, Mette Zander5, Eva Prescott2. 1. Department of Cardiology, Bispebjerg University Hospital, University of Copenhagen, Copenhagen, Denmark. Electronic address: hannah.elena.suhrs@regionh.dk. 2. Department of Cardiology, Bispebjerg University Hospital, University of Copenhagen, Copenhagen, Denmark. 3. Department of Endocrinology, Hvidovre University Hospital, University of Copenhagen, Copenhagen, Denmark. 4. NNF Center for Basic Metabolic Science and Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. 5. Department of Endocrinology, Bispebjerg University Hospital, University of Copenhagen, Copenhagen, Denmark.
Abstract
BACKGROUND:Coronary microvascular dysfunction (CMD) is associated with adverse cardiovascular outcomes and CMD is a hallmark of type 2 diabetes. Liraglutide improves cardiovascular prognosis through partly unknown mechanisms. We hypothesized that treatment with liraglutide improves CMD and symptoms through weight loss, in non-diabetic overweight patients with angina and no obstructive coronary artery disease (CAD). METHODS: We included 33 non-diabetic overweight women (BMI > 25) with CMD (Coronary flow velocity reserve (CFVR) ≤2.5), angina symptoms and no obstructive CAD, in an open-label proof-of-concept study. The protocol included a control period of 5 weeks followed by an intervention period with liraglutide aiming at 3 mg daily for 12 weeks. Participants were investigated before and after the control period and again 1-2 weeks after last liraglutide dose. Primary outcomes were change in CFVR and change in angina symptoms measured by the Seattle Angina Questionnaire (SAQ) in the intervention period compared with the control period. (clinicaltrials.gov, NCT02602600, and ethically approved). RESULTS:Twenty-nine participants completed the study. Liraglutide treatment led to a significant weight loss (mean 6.03 kg (95%CI: 5.22;6.84)) and decrease in systolic blood pressure (mean 10.95 mm Hg (95%CI: 4.60;17.30)). Baseline median CFVR was 2.30 (IQR 1.91;2.51) and remained unchanged after liraglutide treatment (mean change 0.07 (95%CI: -0.07;0.21)). There were no effects on symptoms measured by SAQ or parameters of left ventricular systolic as well as diastolic function. CONCLUSIONS: Treatment with liraglutide led to significant weight loss and lowering of blood pressure with no concomitant symptoms alleviation during treatment and no improvement in coronary microvascular function.
RCT Entities:
BACKGROUND:Coronary microvascular dysfunction (CMD) is associated with adverse cardiovascular outcomes and CMD is a hallmark of type 2 diabetes. Liraglutide improves cardiovascular prognosis through partly unknown mechanisms. We hypothesized that treatment with liraglutide improves CMD and symptoms through weight loss, in non-diabetic overweightpatients with angina and no obstructive coronary artery disease (CAD). METHODS: We included 33 non-diabetic overweightwomen (BMI > 25) with CMD (Coronary flow velocity reserve (CFVR) ≤2.5), angina symptoms and no obstructive CAD, in an open-label proof-of-concept study. The protocol included a control period of 5 weeks followed by an intervention period with liraglutide aiming at 3 mg daily for 12 weeks. Participants were investigated before and after the control period and again 1-2 weeks after last liraglutide dose. Primary outcomes were change in CFVR and change in angina symptoms measured by the Seattle Angina Questionnaire (SAQ) in the intervention period compared with the control period. (clinicaltrials.gov, NCT02602600, and ethically approved). RESULTS: Twenty-nine participants completed the study. Liraglutide treatment led to a significant weight loss (mean 6.03 kg (95%CI: 5.22;6.84)) and decrease in systolic blood pressure (mean 10.95 mm Hg (95%CI: 4.60;17.30)). Baseline median CFVR was 2.30 (IQR 1.91;2.51) and remained unchanged after liraglutide treatment (mean change 0.07 (95%CI: -0.07;0.21)). There were no effects on symptoms measured by SAQ or parameters of left ventricular systolic as well as diastolic function. CONCLUSIONS: Treatment with liraglutide led to significant weight loss and lowering of blood pressure with no concomitant symptoms alleviation during treatment and no improvement in coronary microvascular function.
Authors: Joshuan J Barboza; Mariella R Huamán; Beatriz Melgar; Carlos Diaz-Arocutipa; German Valenzuela-Rodriguez; Adrian V Hernandez Journal: J Clin Med Date: 2022-05-25 Impact factor: 4.964
Authors: Kira Bang Bove; Malin Nilsson; Lene Rørholm Pedersen; Nicolai Mikkelsen; Hannah Elena Suhrs; Arne Astrup; Eva Prescott Journal: PLoS One Date: 2020-11-05 Impact factor: 3.240